Obesity is a chronic low-grade inflammatory disease (both at the systemic and adipose tissue level) that continues to rise worldwide. It is associated with an abundance of comorbidities, including type 2 diabetes (T2D). Bariatric surgery, which induces modifications of the intestinal tract, is to date the most successful treatment for obesity. Its use has dramatically increased in number as it enables both weight reduction and metabolic improvements, with 60% of patients even achieving diabetes remission. Several mechanisms are actually demonstrated to be involved in those clinical improvements. Importantly, both obesity and T2D share many phenotypic characteristics, including increased systemic and adipose tissue inflammation, as well as gut microbiota dysbiosis. These characteristics are deeply modulated after bariatric surgery. This review will address the host metabolic changes observed after bariatric surgery, focusing on the induced gut architectural changes, as well as on the modifications of the inflammatory tone and the gut microbiota.
Introduction
The obesity epidemic and its related comorbidities, including metabolic alterations, type 2 diabetes (T2D), cardiovascular diseases, and some cancers, continue to rise unabated [1] . Obesity is a low-grade inflammatory disease, in part due to inflammatory injuries in the adipose tissue (AT) contributing eventually to moderate but chronic systemic inflammation (i.e., cytokines and circulating immune cells). Obesityassociated low-grade inflammation has a critical role in obesity-related complication development [2] . Major progresses have been made in understanding the timeline of events leading to the onset and maintenance of adipose tissue inflammation and its links with AT structural alterations and systemic metabolism, which this has been frequently explored on mouse models. Briefly, adipocyte size increases during weight gain and participates to inflammatory cytokine production (such as tumor necrosis factor alpha (TNFα)) and chemokines (as the monocyte chemoattractant protein 1 (MCP-1)) [3, 4] , which recruit inflammatory cells within the AT. Macrophages [5, 6] probably account for the vast majority of AT inflammatory cells (as reviewed previously [7] ) and display a mixed surface marker phenotype (M1 and M2) in human obese subjects [8] . Yet, they produce a myriad of proand anti-inflammatory cytokines [9, 10] . Among the overall infiltrating AT macrophage, those organized in crown-like structures, which are also increased in obesity, are resolutely pro-inflammatory [11] . These cellular alterations in subcutaneous AT (scAT) are exacerbated in obese individuals with impaired glucose tolerance or T2D [6, 11, 12] . Visceral AT (vAT), an adipose depot critically related to T2D and nonalcoholic fatty liver disease (NAFLD) [13] , is more inflammatory than scAT [5] . Perturbations of adipose cellular cross talk further contribute to maintain low-grade inflammation and altered metabolism. As such, adipocytes-macrophages cross talks increase the inflammatory tone via (1) interleukin (IL) 1β production by macrophages and inflammasome activation in the adipocytes [14] and (2) macrophages toll-like receptor 4 (TLR-4) activation by adipocyte-released saturated free-fatty acids [4] . IL1β production contributes to adipocyte insulin resistance.
In addition to macrophages, other inflammatory cell types, including lymphocytes [15] , mastocytes [16] , and neutrophils [17] , contribute to a perpetual inflammatory cycle and related perturbed adipose tissue metabolism in obesity. This includes, for example, an increased ratio of helper T cells 1/helper T cells 2 (Th1/Th2) that is associated with increased markers of insulin resistance [18] . Adipose tissue lymphocytes also produce IL-22 and IL-17, two interleukins that enhance macrophage IL-1β secretion in obese T2D patients [15] . Through IL-1β secretion, macrophages, in return, induce the upregulation of IL-22 and IL-17 surface receptors on lymphocytes [4] . The order of events has been suggested to be as follows: T cells are recruited and activated within the AT, inducing macrophage accumulation, and this pro-inflammatory activation contributes to insulin resistance development [19] . This sequence is nevertheless debated as reviewed in [20] .
Recently, the gut microbiota (GM) has emerged as a new contributor to weight gain and immune/inflammatory system imbalances. This concept has been demonstrated through fecal transfer experiments using mice [21] or human [22] donors and germ-free mice recipients and suggests that fecal GM may impact energy metabolism and immune cell activation in the AT (reviewed in [23] ). An increasing number of studies has further demonstrated that a non-negligible proportion of obese subjects exhibit GM dysbiosis. This fecal GM phenotype is characterized by (1) decreased microbial gene richness (MGR) [24, 25] that worsens with the severity of obesity and metabolic alterations [26] and (2) a switch in bacterial composition with a respective increase and decrease of species with pro-inflammatory and anti-inflammatory properties [25] . Moreover, in genetically or high-fat diet-induced obese mice, an increased intestinal permeability and subsequent translocation of bacteria and bacterial components into the systemic compartment was found to lead to increased circulating lipopolysaccharide (LPS) (termed Bmetabolic endotoxemia^) and accumulation of AT macrophages. Both dysbiosis and altered intestinal barrier may thus contribute to the inflammatory tone and related metabolic alterations [27] [28] [29] . In human obesity, however, this concept is still challenged as intestinal permeability is only subtly altered in fasting conditions, but it appears to worsen dramatically after a lipid challenge and associates with increased systemic inflammation and T2D [30] .
Bariatric surgery (BS) represents a relevant model of rapid weight reduction combined with metabolic and inflammatory improvements. Recent data has also shown some improvements of GM dysbiosis, although only partial [26] .
However, whether bariatric surgery-induced improved metabolism is firmly related to the changes of systemic and tissue inflammatory tone, as well as GM dysbiosis rescue, need detailed examination. In the current review, we focus on the effects of BS on T2D, GM, and inflammation modifications and address whether these events can be connected.
Bariatric surgery and type 2 diabetes improvement
Lifestyle modifications and/or dietary intervention are in general not sufficient to induce major and sustainable weight loss and often result in weight regain [31, 32] . The increasing prevalence of severe forms of obesity [33] , yet this has not been implemented in every country's national guidelines [36] . Currently, BS can be divided into two main procedures: (1) either purely restrictive, with laparoscopic adjustable gastric banding (AGB) and vertical sleeve gastrectomy (VSG) or (2) using both restrictive and malabsorptive mechanisms, with Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion [37] . RYGB and VSG are the most widely performed types of BS worldwide [34] and as such, we will focus on these procedures, whereas LAGB constitute a good weight loss control model. Although VSG and RYGB display low and similar rates of complications, mortality [38] , and comparable short term weight loss [39] , RYGB tends to achieve greater weight loss and metabolic improvement in the longterm [39] .
An abundance of literature demonstrates the major beneficial effects of BS in inducing major and durable weight reduction [40] [41] [42] , in decreasing mortality [43] and improving many obesity-related comorbidities. As T2D improves rapidly and more significantly following BS than with intensive medical therapy [44], a new clinical concept has emerged: diabetes remission (DR), which is defined as the normalization of glycemic parameters in the absence of glucose-lowering agents 1 year post-BS [45] . DR occurs in around 60% of T2D 1 year post-BS, yet this percentage varies according to type of surgery [46] . Randomized controlled trials have demonstrated that, compared to intensive medical care, RYGB and VSG both improve glucose control, as seen by the number of patients reaching their HbA1c target. However, post-RYGB, more patients are able to remain free of glucose-lowering drugs (i.e., achieving DR) as compared to post-VSG patients [47] . Even in patients not reaching DR, a significant improvement of glycemic control is nevertheless observed, as evidenced by the reduction in HbA1c [48, 49] Figure 1 condenses the different mechanisms currently described as implicated in the metabolic improvements which are discussed below. 
Changes in hormones and beta cell function
In addition to their role in the control of food intake, the impact of gut hormones on insulin secretion and insulin resistance have been abundantly described in the literature Literature on adaptive changes of pancreatic insulin secretion post-BS started with the exploration of subjects with hyperinsulinemic hypoglycemia complications post-RYGB. Service et al. described an increased β-cell mass (i.e., nesidioblastose) upon resecting the pancreas in six patients suffering from neuroglucopenic symptoms of post-prandial hypoglycemia post-RYGB [96] . Since then, whereas some studies confirmed this first finding [97] , others observed no change in pancreatic β-cell mass [98, 99] post-BS. These diverging results might originate from the difficulty in directly assessing pancreatic tissue in humans. Some groups have thus evaluated β-cell mass or function using tomography or magnetic resonance imaging to assess pancreatic triglyceride content [100] coupled with functional exploration (C-peptide production and insulin sensibility) [99] . Rather than increase observed previously, a decrease in pancreatic β-cell mass was shown due to the reduction in pancreatic steatosis and decreased pancreatic insulin content, a phenomenon suggested to be linked to pancreas adaptation following weight loss. Similarly to heterogeneous findings in humans, animal model studies report either enhanced [101, 102] or decreased [95, 103, 104] β-cell mass post-BS. Differences in insulin resistance status may explain such variability with decreased β-cell mass observed solely in humans or mice who predominantly improved their insulin sensibility. Nevertheless, despite the major improvement in glucose homeostasis, β-cell function is not rescued by BS and remains dysfunctional as compared to lean normoglycemic subjects [105] . Along with weight regain [48] , persistent β-cell dysfunction could participate in T2D relapse observed during follow-up, in agreement with findings demonstrating that T2D severity and duration [48] contribute to diabetes non-remission.
Interestingly, glucagon-like peptide-2 (GLP-2) is also proposed to be involved in the metabolic improvements. GLP-2, co-expressed with GLP-1 in intestinal L cells and released upon nutrient ingestion, has a beneficial trophic role on the small intestine with stimulation of crypt cell proliferation, increased bowel weight, and villus growth of both the jejunum and the ileum [106, 107] . Plasma GLP-2 significantly increases post-RYGB, concomitantly with increased crypt cell proliferation [108, 109] ; thus, GLP-2 may participate to the gut hypertrophy induced by BS. GLP-2 also displays a protective effect on gut barrier function and inflammation [28] . Using prebiotics in obese mice induces higher GLP-2 circulating concentration, lower plasma LPS, and decreased systemic and hepatic inflammation together with metabolic improvements [28] . Pharmacologic agonist GLP-2 treatment reproduced the beneficial effect of the prebiotic treatment [28] . In humans, the therapeutic injection of GLP-2 in small bowel disease also results in significantly improved nutrient absorption, which is probably due to improvements in gut function and reduced inflammation [110] . Since GLP-1 and GLP-2 are co-secreted, one could wonder whether the physiological response to the anatomic changes induced by BS could be explained by enhanced GLP-2 secretion to restore the gut anatomy with GLP-1 secretion being merely driven by this adaptive effect.
Enteroplasticity and gut remodeling
Each section of the intestine is highly and functionally specialized, with nutrient absorption occurring generally in the proximal to mid-intestine (i.e., duodenum/jejunum) whereas the gut barrier and gut peptide secretion are likely more important along the distal intestine. The intestinal mucosa is organized into a stratified inner and a larger outer layer, which is where most commensal bacteria are hosted, thus enabling the cross talk between the host and the environment. The intestine is highly plastic, as it has been shown that large surgical ileal removal [111] induces an increased cellular proliferation to increase glucose uptake. Both RYGB and VSG modify the gut anatomy, and various mouse studies using different BS techniques have described an intestinal adaptation post-BS. Whereas the non-alimentary bypassed limb tends to atrophy [112] , both the alimentary and common limb show signs of hyperplasia (up to 40% weight gain, higher villus height and crypt depth, signs of proliferation, increased L cell number without changes in L cell density) post-RYGB [108, [112] [113] [114] . By contrast, whereas VSG does not induce gut hypertrophy, it results in increased number and density of enteroendocrine L cells [115] .
The increased number of intestinal proglucagon-derived peptide secreting cells post-BS agrees with the above described increase of gut hormones secretion post-BS. Despite hormonal changes, modifications of nutrient sensing by the remodeled gut are also suggested to be involved in the improvement of glucose metabolism post-RYGB. Troy et al. suggested that duodenojejunal bypass enhanced intestinal neoglucogenesis and portal glucose sensing thus resulting in improved insulin sensitivity [116] . More recently, it was demonstrated that BS-induced gut remodeling is different according to the BS techniques. RYGB induces intestinal hyperplasia and increased glucose uptake through increased glucose transporter 1 (GLUT-1) at the basolateral membrane of enterocytes [115] to support tissue growth [117] . By contrast, VSG is not associated with intestinal hyperplasia yet VSG mice display delayed glucose absorption. Finally, recent evidence demonstrates that bile diversion also plays a role in the decrease of intestinal glucose uptake post-RYGB [118] . Finally, since endogenous sodium contained in bile acids is necessary for glucose uptake by sodium glucose cotransporter 1 (SGLT1), it was recently demonstrated that glucose uptake (via SGLT1) occurred only in the common limb post-RYGB, thus reducing the total intestine glucose uptake and therefore improving plasma glucose.
Bile acids
Bile acids (BA) are synthetized in the liver, stored in the gallbladder, and delivered to the duodenum in response to nutrients. BA act as surfactants and play a critical role in lipid absorption. Furthermore, BA have a positive impact on pancreatic function since they are able to trigger GLP-1 secretion, through their action as natural ligands on the Takeda G protein-coupled membrane receptor (TGR5) receptor expressed in intestinal L cells [119] . Both RYGB and VSG induce modifications of fasting and post-prandial BA serum concentration and composition [103, [120] [121] [122] [123] , whereas LAGB solely reduces serum BA [120] . Although endoluminal concentration of BA post-BS does not seem to be modified in animal models [124] , this needs to be evaluated in humans, especially because the BA composition differs between rodents and human. Interestingly, intrajejunal bile infusion of taurocholic acid can experimentally lower blood glucose concentration and enhance GLP-1 secretion and C-peptide/glucose ratio [125] in healthy men.
Indirect proof of the involvement of BA on weight loss and improved glucose tolerance has been demonstrated using TGR5 and farnesoid X receptor (FXR) KO mice submitted to VSG, BA being another natural ligand for FXR [119] . In TGR5 −/− mice, VSG fails to induce improvements in body weight, fasting glycemia, and glucose tolerance [103] , thus suggesting the importance of the TGR5 signaling pathway in the improvement of glucose homeostasis post-BS. The proposed mechanism of BA underlying BS-induced improvements in body weight and metabolism includes the reduction of systemic and hepatic inflammation, which would improve insulin signaling, but not the increase of GLP-1 nor that of insulin secretion [103] . Furthermore, FXR −/− mice undergoing VSG display impaired reduction of fasting glycemia and glucose tolerance [122] . This further suggests the importance of FXR in the improvement of glucose homeostasis post-BS. However, the complete physiological mechanisms are clouded by pharmacological studies administering agonists and antagonists of intestinal FXR displaying similar clinical effects. Indeed, both the inhibition of the intestinal FXR with either tauro-beta-muricholate (T-beta-MCA) [126] or glycoursodeoxycholic acid (GUDCA) [127] , or the selective intestinal FXR agonist using fexaramine [128] improve metabolic disorders in mice fed a HFD [126] [127] [128] . Notably, the improvement of glucose homeostasis in these pharmacological studies could merely originate from the induced weight loss or at least reduced weight gain and reduction of systemic inflammation [128] . While BA are ligands for FXR and TGR5, ultimately, the pool of bile acids (secondary vs. primary) are largely important for how BA affect these signaling pathways. Most importantly, BA can influence microbiota composition, and microbiota reciprocally influence the BA pool through FXR [122, 129] ; thus, it is important to examine BA in parallel with the gut microbiota.
Change of gut microbiota after bariatric surgery
Gut microbiota compositional modifications
Remarkable shifts in the gut microbiota (GM) composition have been consistently described post-BS in both short-term [130] [131] [132] [133] or long-term (> 5 years) studies [26, 134] ; however, there is a major inter-individual variability [135] . There is no doubt that those modifications might be partly driven by the drastic modulation of the gut architecture [136] as well as food intake reduction [24], hormonal and bile acid modification, and eventually low-grade inflammation changes. Importantly, because drugs impact microbiota composition [137] , their change or even cessation due to BS-induced metabolic improvement might also account for major GM modifications post-BS. Yet, this has, to date, never been examined in BS studies. For example, metformin has largely been shown to influence GM composition in both mice [138] and humans [139] . As some patients experience DR post-BS, they are able to discontinue their glucose-lowering agents following BS [48] , which could account for differences in GM profiles as compared to patients not achieving DR. Likewise, proton pump inhibitors (PPIs), systematically prescribed during the first months post-BS, induce GM modifications [140, 141] by increasing oral bacteria [142] , a modification already observed post-BS [131, 143] .
A recent meta-analysis [132] summarized the changes in GM composition post-BS and showed that among the plethora of bacterial changes, two genera, Escherichia and Akkermansia, have been consistently reported to strongly increased post-BS [132] . Akkermansia muciniphila abundance is associated with insulin sensitivity and decreased inflammation in several studies [144, 145] [130] . However, whether the increase in the proportional abundance of these bacteria species in the GM is causally linked to improved glucose metabolism is unknown. Unpublished data from our team revealed that the marked increase in Akkermansia muciniphila seen after RYGB, but not LAGB, is not related to improved insulin sensitivity markers (Dao et al., in revision), albeit in severely obese subjects with marked dysbiosis that only partially improves after BS. In this context, a hallmark of GM modifications post-BS is the increase in microbial gene richness (MGR) [26, 131] with drastic amelioration of insulin sensitivity, adiposity, BMI, and systemic inflammation [24, 26, 131] . However, morbidly obese patients post-BS do not normalize their bacterial richness in proportion to their metabolic improvements [26] .
In the context of T2D remission, only one study has focused on the comparison of microbial changes between patients experiencing or not experiencing DR post-BS [147] . Even though only 14 patients were examined (7 RYGB, 7 VSG), Murphy et al. showed that pre-surgical GM composition differed between patients who eventually experienced DR as compared to those who did not. Postsurgery, individuals experiencing DR had increasing levels of the genera Faecalibacterium (only RYGB) and the species Roseburia intestinalis (both RYGB and VSG), both of which have already been associated with decreased lowgrade inflammation and improved glucose homeostasis in both humans and rodents [122, 130] .
Although there is no doubt that GM composition is significantly changing post-BS, this association does not (1) confirm the involvement of GM in metabolic improvements found post-BS nor (2) provide insights into the potential mechanisms involved. To decipher the relationship between the host metabolic improvements, BS, and GM, fecal microbiota transplantation (FMT) appears a relevant tool to explore causality.
Fecal transplantations effects
FMT has been scarcely studied post-BS [134, 148, 149] , and only two studies provide information related to glucose homeostasis improvement [148, 149] . FMT from either post-RYGB or sham-operated obese mice into germ-free mice leads to decreased adiposity in the animals receiving post-RYGB feces. A recent study performing FMT from human to mice confirmed this effect [134] . Germ-free mice receiving FMT from patients who had undergone BS up to 9 years before gained less adiposity than those receiving FMT from nonoperated obese individuals [134] . Additionally, RYGB recipients displayed decreased circulating insulin levels and HOMA-IR, while the opposite could be observed for the Sham-recipient [148] , suggesting that post-BS GM could replicate some metabolic benefits of the surgery. Finally, Arora et al. performed two different FMT experiments from BS or sham-operated obese fa/fa rats (which are severely obese due to genetic alterations on the leptin receptor) into germ-free mice, transferring either the ileum or the cecum content as inoculum [149] . They showed that the ileal FMT (from RYGB) increased both the α-diversity and fat mass, yet altered their glucose tolerance as compared to that of ileal sham controls. By contrast, cecal FMT post-RYGB induced a significant decrease in post-prandial glucose excursion, yet there was no significant effect on weight as compared to the cecal sham control FMT. This apparent discrepancy between these observations and those previously reported by Liou et al. could also originate from the differences in the models (mice vs. rats and diet-induced obesity vs. genetic obesity and T2D) [148] . These promising yet conflicting results underline the need for replicative studies, and while further research is needed to fully determine the factors affecting GM composition following surgery, the switch in GM functionality may be a more important factor that impacts clinical outcomes post-BS.
Gut microbiota functional modifications
Metabolic endotoxemia and gut barrier improvements As previously described, obesity and T2D are associated with increased gut permeability [27-29] in both mice and humans. For the latter, this occurs mostly after a lipid challenge [30] . This phenomenon is mainly driven by lipopolysaccharides (LPS), an outer membrane molecule of gram negative bacteria, which triggers inflammation via the TLR4/CD14 complex [27] [28] [29] . Literature has repeatedly reported the decrease of systemic LPS post-BS [150] [151] [152] [153] [154] , which has even been associated with improvements in insulin resistance and glucose control [151, 153] . A recent murine study demonstrated that RYGB induced the improvement of tight-junction integrity and improved in vivo intestinal permeability together with the reduction of metabolic endotoxemia and systemic inflammation [155] . This improved intestinal permeability could originate from (1) the observed reduction of fat intake post-BS [156] as fat intake indeed alters the gut barrier [27, 30] or (2) the increased Akkermansia muciniphila observed post-BS. While this latter factor needs to be further explored, supplementing mice with alive or pasteurized A. muciniphila is able to reduce plasma LPS and is associated with improvements of the gut barrier as well as glucose metabolism [138, 144] . Whether this is a possible mechanism in BS-induced metabolic improvement remains unknown.
Bile acids
As mentioned above, BA have an impact on glucose homeostasis post-BS and are strongly connected to GM composition. Experiments using germ-free or antibiotic-treated mice demonstrated the obligatory role of the GM to ensure the physiological production of unconjugated and secondary BA [129, 157] . As GM dysbiosis contributes to altered BA metabolism in inflammatory bowel diseases (IBD), one could wonder whether the same is also occurring in other diseases presenting with GM dysbiosis, such as obesity [145] or T2D [158] . Importantly, BS induces an increase in circulating conjugated BA in humans and rodents [103, [120] [121] [122] [123] which acts partly through FXR to improve glucose tolerance post-BS [122] . FXR KO mice submitted to VSG displayed differences in GM composition such as lower levels of Roseburia spp. [122] as compared to their wild-type counterpart. Most importantly, GM functionality linked to BA metabolism was demonstrated to significantly differ between RYGB and obese individuals without surgery. Specifically, they observed an increased abundance of microbial genes involved in the production of secondary BA, concomitantly with increased postprandial levels of BA and fibroblast-growth factor 19 (FGF-19) post-RYGB, the latter of which is an intestinal hormone that regulates BA pools via FXR [134] . However, the link between the modifications of BA and GM had not been evaluated in this study. More recently, GUDCA has been demonstrated to be an intestinal FXR antagonist and is increased upon metformin treatment and improves glucose tolerance. Importantly, it was recently demonstrated that metformin improves glucose tolerance via the decrease of Bacteroides fragilis abundance which itself is correlated to GUDCA levels and acts through FXR signaling [127] . They further showed that FMT using feces of metformin-treated patients increases insulin sensitivity and levels of intestinal tauro-β-muricholic acid (TβMCA) in antibiotic-treated mice, whereas FMT using untreated patients was deleterious, similarly to the inoculation with B. fragilis which abrogated the beneficial effects of metformin on BA levels [127] . It is thus possible, yet unproven, that GM evolution post-BS is implicated in the observed increase of GUDCA or TβMCA, which further suggests a metformin-like action of BS on glucose homeostasis. Nevertheless, whether BS induces modification of Bacteroides fragilis and could therefore explain partly the improvement in glucose metabolism observed post-BS has still not been described to date.
Branched chain amino acids
Branched chain amino acids (BCAA) are essential amino acids such as leucine, isoleucine, and valine, consisting up to 20% of daily amino acid intake. Although beneficial effects of BCAA supplementation have been described [159] [160] [161] , other studies also show increased BCAA levels in obesity [22, 162] , insulin resistance, and T2D [158, [163] [164] [165] [166] [167] . BCAA mediate IR through the activation of the mammalian target of rapamycin complex 1 (mTORC1) and its downstream target, the ribosomal protein S6 kinase beta-1 (S6K1). mTORC1 and S6K1 induce insulin resistance via the inhibition of phosphorylation of the insulin-receptor (IRS-1) [168, 169] . BCAA are implicated in pancreatic beta cell proliferation in the presence of increased glucose [170] . Relationships between GM, serum BCAA, and insulin resistance are also suggested [22, 163, 171] . Patients with insulin resistance display increased levels of serum BCAA together with a GM enriched in Prevotella copri and Bacteroides vulgatus, which are two species harboring increased expression of genes involved in the biosynthesis of BCAAs and reduced expression of genes for internal BCAA use [163] . Most importantly, our team demonstrated that RYGB induces a reduction in serum BCAAs, demonstrating another potential mechanism of BS to improve glucoserelated parameters [26] . This decrease in BCAAs is also observed post-BS in several other studies [172] [173] [174] [175] [176] [177] [178] . Moreover, RYGB also induces an improvement in microbial gene richness which was at baseline significantly associated with increased Bacteroides vulgatus [26] . Similarly, we found positive associations between this species and metabolic deterioration in severe obesity.
Most interestingly, Laferrère et al. demonstrated that BCAA decreased significantly solely in patients who lost at least 10 kg of body weight post-BS, but not in patients with a similar weight loss induced by a restrictive diet [172] , suggesting the role of a BS-dependent mechanism in BCAA reduction. Whether the reduction in BCAA post-BS could be another weight lossindependent factor implicated in the resolution of T2D and implicating the GM would need demonstration. Indirect support of this is that reducing BCAAs have beneficial effects on glucose control independent of weight loss. As well, several experiments demonstrated that glucose-lowering drugs such as metformin [179, 180] and glipizide [180] promote the upregulation of BCAA degradation pathways, also leading to a decreased serum BCAA [179] .
Inflammatory changes post-BS: links with improvement in T2D?
Adipose tissue remodeling As depicted in Fig. 2 , BS enables a dramatic loss in body fat mass [67] involving both the scAT and vAT depots [5] . It was initially described that AT undergoes significant remodeling during BS and that BS reduces adipocyte size, yet more effectively in DR patients [181] . Although the relationship has not been firmly confirmed, reduced adipocyte size might contribute to the reduced production of cytokines such as IL-1Ra [182, 183] or IL-8, IP-10, monokine-induced by γ-interferon (MIG), MCP-1, and BRegulated on Activation, Normal T Cell Expressed and Secreted^(RANTES), along with the improvement of body weight and metabolic alterations. Moreover, BS is associated with fewer macrophages in the scAT [183, 184] and in the vAT [185] and a switch toward a less proinflammatory profile [8, 184] , which may also participate in the reduced inflammatory tone post-BS. T2D patients undergoing long-term DR lose more total fat mass and trunk-fat mass than those remaining T2D post-RYGB, suggesting a possible role of vAT modifications in DR [48] . This result is concordant with that of a previous study where the remission of metabolic syndrome (pre-diabetes state) was observed in patients who lost the most vAT mass post-RYGB [186] .
Notably, a recent study demonstrated that, while obese mice on a dietary restriction can normalize their body weight, they do not fully rescue their insulin sensitivity profile nor AT inflammation with the conservation of crown-like structures. Moreover, macrophages still display an inflammatory profile with a perpetual cross talk with T cells maintaining inflammatory activation [187] . These results, that need to be confirmed in human, suggest that although weight loss improves obesityinduced AT injuries, it does not restore its structure and function, which is important in the context of BS as some individuals do not normalize their BMI post-BS [40, 48] . In addition, it is well-known that BS induces major inter-individual variability in clinical outcomes and weight response, one could speculate that patients undergoing DR would improve AT inflammation and metabolism better than those not achieving DR and with persistent inflammatory alterations.
Circulating immune and cytokine production changes
Together with changes in inflammation in the AT, modifications of circulating immune cells and inflammatory cytokines are observed post-BS. Blood CD16+ monocytes, known to display an increased inflammatory cytokine production, are increased during obesity [188] and positively correlates with BMI [189] and the specific CD14dim CD16+ subpopulation further augments in obese individuals with T2D [188] . Interestingly, the CD14dim CD16+ subpopulation exhibits the lowest lipid accumulation capacity of all monocytes and is less prone to migrate into the AT [190] . BS significantly reduces these two subpopulations and most particularly the CD14dim CD16+ monocytes [188, 191] while switching their secretory profile toward a decreased production of inflammatory cytokines such as TNFα and IL6 [191] . Interestingly, Chen et al. recently showed significant associations between changes in GM composition post-BS (assessed by RT-PCR) and the changes in monocytes number, secretion profile, and the expression of their membrane receptors such as TLR-4, which is the receptor that recognizes bacterially-produced LPS, and thus involved in microbiota signalization pathway [191] .
Circulating T lymphocytes display a Th1 inflammatory profile during obesity [18] and also undergo phenotype modifications post-BS. Whereas the circulating number of lymphocytes is not modified, Th1 cells and the Th1/Th2 ratio decreases significantly post-BS-induced weight loss [192] (Fig. 2) . This decrease is stronger among patients with T2D or impaired glucose tolerance (IGT) than normoglycemic patients pre-BS [192] . In agreement with a switch in inflammatory profile, the magnitude of glycemic improvement post-BS is correlated with the increase in Th2 post-BS in a clinical study focusing on T2D or IGT patients [193] . Blood levels of a specific T cell type, mucosal-associated invariant T (MAIT) cells, are dramatically decreased in obese and obese T2D patients [194, 195] but display a Th1 and Th17 cytokine production profile [194] while their number is increased in the AT. The relationship between MAIT cells and hyperglycemic milieu was substantiated by an in vitro study showing that hyperglycemia per se induces MAIT apoptosis [195] , which could partly explain their reduction during obesity and T2D. Interestingly, MAIT cells recognize microbial derived metabolites (originating from the riboflavin pathway) that are able to activate these cells. Recently, it was also demonstrated that MAIT cells could be activated by some bacterial species [196] . RYGB is able to (1) increase the number of MAIT cells, yet their level does not return to that of normal healthy controls, and (2) nearly normalize their cytokine secretion profile with the exception of IL-17 [194] , concomitantly with weight loss and improvements in glycemic control. Overall, the inflammatory tone as well as the inflammatory profile of circulating and AT immune cells tend to decrease post-BS.
Conclusions and perspectives
In this review, we ought to describe the beneficial effects of BS in terms of glucose control improvement and diabetes remission, as well as the myriad of complex mechanisms probably acting in synergy to improve glucose homeostasis. BS induces caloric restriction, weight loss, fat mass loss, improved β-cell function, gut plasticity, both hormonal and bile acids changes, as well as immune cell modifications at the systemic level and within the adipose tissue. However, the causal or secondary contribution of these factors in improved glucose metabolism still need to be deciphered. Recently, GM dysbiosis was shown to be partially improved after BS, however, not to the same degree as metabolic improvements. Thus, whether the GM per se plays a role in DR observed post-BS still remains to be proven. Additionally, the mechanisms by which GM compositional and functional modifications post-BS participates in improved glucose metabolism and/or inflammatory tone still need to be evaluated in depth in controlled studies focusing on the combination of mechanisms proposed above in this review. Exploring these interactions will also help identifying targets for biomarkers or upstream therapeutics mimicking BS effects without surgical intervention.
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